Latest Breaking News On - Institute gustave roussy - Page 1 : comparemela.com

Why we need to rethink how we talk about cancer

Naming metastatic cancers after parts of the body could be holding up research and preventing people from accessing the best treatment Hear the biggest stories from the world of science | 4 February 2024

OSE2101 Cancer Vaccine Yields Favorable OS vs SOC in HLA-A*02+ ICI-Resistant NSCLC

Benjamin Besse, MD, PhD, discusses the results from the ATALANTE-1 trial and details the mechanism of action of the OSE2101 vaccine.

Celcuity Announces Plan to Conduct Phase 1b/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer

22.08.2023 - - Received FDA clearance of IND for gedatolisib in combination with darolutamide - Virtual Science Day to be held on September 21, 2023 from 10:00 a.m. – 12:00 p.m. ET MINNEAPOLIS, Aug. 22, 2023 (GLOBE NEWSWIRE) - Celcuity Inc. (Nasdaq: CELC), a . Seite 1

Analyzing Kaleido Biosciences (KLDO) & Its Peers

MET status may predict benefit of amivantamab-lazertinib therapy in lung cancer subset

CHICAGO — MET status by immunohistochemistry may predict how patients with osimertinib-treated EGFR-mutated non-small lung cancer will respond to subsequent combination therapy, according to findings presented at ASCO Annual Meeting.Patients with MET-positive status appeared five times as likely as those with MET-negative status to respond to amivantamab (Rybrevant, Janssen) plus lazertinib